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012.11.00Abstract Aim of the work: To assess serum concentrations of triggering receptor expressed on
myeloid cells-1 (sTREM-1) in rheumatoid arthritis (RA) patients, and correlate them with the main
clinical, serological, radiological features and functional capacity of RA patients.
Patients and methods: Sera from 61 RA patients, and 30 healthy controls were assayed for
sTREM-1 by Enzyme Linked Immunosorbant Assay. RA disease activity was assessed using 28-
joint disease activity score (DAS-28). Assessment of patient’s functional capacity was done using
modiﬁed health assessment questionnaire (mHAQ). Standardized X-rays were done to all RA par-
ticipants and evaluated according to Larsen score
Results: Serum levels of sTREM-1 were signiﬁcantly higher in RA patients vs healthy controls
(57.61 ± 28.87 and 43.72 ± 10.64 ng/ml; p= 0.027). These levels were higher in patients with
severe disease activity (68.27 ± 36.14 ng/ml) than those with mild and moderate disease activity
(43.50 ± 6.49 ng/ml and 47.52 ± 12.26 ng/ml, respectively; p= 0.008). On the contrary, no signif-
icant difference was found in levels of sTREM-1 in patients with extra-articular involvement or
positive RF than those without. Levels of sTREM-1 showed a highly signiﬁcant positive correlation
with DAS-28 (P= 0.001), ESR (P= 0.02) and mHAQ (p= 0.003).There were no signiﬁcantding 6, Makka St., El Sefarat
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96 S.A. El Bakry et al.correlations between sTREM-1 level with age, disease duration, morning stiffness, nor radiological
narrowing and erosion scores.
Conclusion: Levels of sTREM-1 were elevated in RA patients and correlated signiﬁcantly with
clinical and laboratory markers of disease activity as well as functional disability (as determined
by mHAQ). To conﬁrm our results we propose that larger scale, multicenter studies with longer
evaluation periods are needed.
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Rheumatoid arthritis (RA) is an inﬂammatory disease charac-
terized by abnormal synovial hyperplasia and inﬂammatory
cell inﬁltration into the synovium, which causes joint inﬂam-
mation and subsequent destruction [1]. When synovial inﬂam-
mation is initiated, RA ﬁbroblast-like synovial cells start to
proliferate and the activated inﬂammatory cells produce vari-
ous pro-inﬂammatory mediators, including cytokines, chemo-
kines and matrix metalloproteinases (MMPs), resulting in the
exacerbation of synovitis and the destruction of joint integrity
[2]. A large number of cytokines are found elevated in the
joints of RA patients. Indeed, it is now clear that these cyto-
kines play a fundamental role in the processes that cause
inﬂammation, articular destruction, and the comorbidities
associated with RA [3,4]. Triggering receptor expressed on
myeloid cells-1 (TREM-1) is a recently identiﬁed molecule in-
volved in monocytic activation and inﬂammatory response. It
is expressed mainly on monocytes and neutrophils, and plays
an important role in amplifying inﬂammatory response in
acute and chronic inﬂammatory conditions [5,6]. TREM-1
expression is increased by various Toll-like receptor (TLR) li-
gands during acute inﬂammation [5]. Human TREM-1 is
formed of an extracellular immunoglobulin (Ig)-like part, a
transmembrane region with a positively charged lysine residue,
and a short cytoplasmic part that does not have any signaling
motifs. Its natural ligand has yet to be identiﬁed, so signaling
and function of TREM-1 were studied using an agonistic anti-
body, which induces receptor cross-linking [7,8]. Apart from
its membrane-bound form of TREM-1, a soluble form of
TREM-1 (sTREM-1) is produced by the proteolytic cleavage
of the extracellular, membrane-bound form. It has been re-
ported that sTREM-1 works as a decoy receptor to prevent
the binding of its ligand to membrane-bound TREM-1 and
to inhibit the effect of TREM-1 activation [9].
The role of TREM-1 in producing and amplifying acute
inﬂammatory response in many septic conditions is well estab-
lished as well as in other several diseases [10–13].
Further, Kuai and colleagues have demonstrated the in-
creased expression of functionally active TREM-1 on inﬁltrat-
ing leucocytes in human RA synovium [14].
In the present study we aimed to measure serum levels of
sTREM-1 inRApatients and to determine its relationwith disease
activity, bone damage and functional capacity of RA patients.2. Patients and methods
2.1. Study design
This is a cross sectional-observational study.2.2. Clinical evaluation
Sixty-one patients with RA were randomly recruited from the
Rheumatology and Rehabilitation Clinic Cairo University and
the Rheumatology Clinic, Internal Medicine Department, Ain
Shams University. All RA patients fulﬁlled the new EULAR/
ACR criteria of 2010 [15]. Thirty healthy subjects were in-
cluded as a control group and they were all age and sex
matched. Patients with infection, malignancy as well as those
with other autoimmune diseases were excluded from the study.
All participants gave written informed consent to participate in
the study, which was approved by our local Ethics Committee.
Patients and controls were subjected to the following: full
medical history and thorough clinical examination (general,
systemic and musculoskeletal). Assessment of RA disease
activity by using 28 tender and swollen joint count disease
activity score (DAS-28) [16] and patients were further divided
according to their DAS-28 into severe, moderate, and mild dis-
ease activity (DAS >5.1, 3.2–5.1 and <3.2, respectively).
Standardized X-rays were done to all participants and joint
damage in RA patients was assessed by Larsen score [17]. As
well, the functional assessment of RA patients was done using
a modiﬁed health assessment questionnaire (mHAQ) [18].
2.3. Laboratory assessment
Routine biochemistry tests were collected from patients’ re-
cords. Complete blood count was done using a Coulter coun-
ter (T660) and ESR was done by the Westergren method.
2.4. Rheumatoid factor (RF)
RF was determined by the latex ﬁxation method. A suspension
of uniform polystyrene particles sensitized in glycine buffer
with heat altered human IgG (BD Diagnostic Systems, Sparks,
Maryland, USA) was incubated with progressive dilutions of
human sera in microtiter wells. After incubation, the plates
were inspected for observable agglutination.
2.5. Serum sTREM level determination
Peripheral venous blood samples were obtained from patients
and controls. After centrifugation at 1000g for 10 min, the ser-
um was frozen and stored at 20 C until assayed on the same
day to eliminate the day to day interassay variability. A com-
mercial Enzyme Linked Immunosorbant Assay (ELISA) kit
(WKEA Med Supplies Corporation; NY; USA) was used for
assaying sTREM levels. This assay employed an antibody
speciﬁc for human TREM coated on a 96-well plate. In brief,
each serum sample was directly transferred to the wells of the
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instructions. The absorbance was measured at 450 nm in a
microtest plate spectrophotometer, and TREM levels were
quantiﬁed with a calibration curve using human TREM as a
standard. Both standards and samples were evaluated in dupli-
cates and the inter-assay variations were shown to be within
the range given by the manufacturer.
Statistical analysis. The Statistical Package for Social Sci-
ences (SPSS) version 10 (LEAD Technology Inc., Charlotte,
NC, USA) was used to analyze the data. Continuous variables
were summarized using the mean ± standard deviation (SD)
values and categorical variables using absolute values and per-
centages. Signiﬁcant differences were calculated using the
Mann–Whitney U test for continuous variables. Spearman’s
rank correlation was used to examine the relationship between
two continuous variables. A difference was considered to be
statistically signiﬁcant when the probability (p) value was
<0.05.
3. Results
Sixty-one RA patients were included in the study. The mean
age was 44.7 ± 10.7 years and 45 were females. Thirty age
and gender matched healthy volunteers were considered as
the control group with a mean age of 44 ± 11.2 years and
21were females. In RA patients, 72% had positive RF and
28% were sero-negative. Other characteristics of RA patients
are displayed in Table 1.
RA patients had higher serum levels of sTREM-1 than con-
trols, being 57.61 ± 28.87 ng/ml and 43.72 ± 10.64 ng/ml,
respectively; p= 0.027 (Fig. 1).
Patients with RA were subsequently divided according to
their grade of disease activity by DAS-28. Seven patients
(11.5%) had mild disease activity, 23 patients (37.7%) had
moderate disease activity while 31 patients (50.8%) had severe
disease activity. Serum levels of sTREM-1 were higher in pa-
tients with severe disease activity (68.27 ± 36.14 ng/ml) than
those with mild and moderate disease activity (43.50 ±
6.49 ng/ml and 47.52 ± 12.26 ng/ml, respectively; p= 0.008)
(Fig. 2).
Twenty-six RA patients suffered from extra-articular man-
ifestations (42.6%). Among them, 11 patients had SC nodules,
10 with Sicca Syndrome, neuropathy was found in ﬁve andTable 1 Characteristics of rheumatoid arthritis (RA) patients
(No = 61).
Parameter Mean ±SD Range
Disease duration (years) 8.1 7.1 1–30
Morning stiﬀness (min) 38.5 69.6 0–300
Tender joints (of 28) 9.1 4.2 0–28
Swollen joints (of 28) 4.6 5.5 0–24
DAS-28 5 1.5 2.21–8.2
mHAQ 0.9 0.7 0–2.75
Hemoglobin (g/dl) 11.7 1.1 9.6–14.6
Leucocytes (·1000/ll) 7.9 2.8 2.4–19.4
Platelets (·1000/ll) 330.3 119.5 153–755
ESR (mm/hr) 52.8 30.9 8–135
DAS: disease activity score, mHAQ: modiﬁed health assessment
questionnaire, ESR: erythrocyte sedimentation rate.interstitial pulmonary disease in six patients. Comparing ser-
um levels of sTREM-1 in patients who had extra-articular
manifestations with those without showed no signiﬁcant differ-
ence (64.28 ± 36.92 ng/ml and 52.65 ± 20.22 ng/ml, respec-
tively; p= 0.165). Similarly, no signiﬁcant difference was
found on comparing serum levels of sTREM-1 in patients with
positive RF and those without (61.43 ± 32.17 ng/ml and
47.71 ± 14.09 ng/ml, respectively; P= 0.08).
Using the Spearman rank correlation analysis (Table 2, Fig
3), serum levels of sTREM-1 showed a highly signiﬁcant posi-
tive correlation with DAS-28 (P= 0.001), ESR (P= 0.02)
and mHAQ (p= 0.003). On the other hand, there were no sig-
niﬁcant correlations between sTREM-1 level and age, disease
duration, morning stiffness, nor radiological narrowing and
erosion scores of the hand joints (p> 0.05). Collectively, ele-
vated sTREM levels were associated with clinical and labora-
tory measures of disease activity in RA patients as well as
functional disability.4. Discussion
Triggering receptor expressed on myeloid cells-1 (TREM-1) is
a recently identiﬁed immunoglobulin-like cell surface receptor
mainly expressed on neutrophils and its expression is increased
by various Toll-like receptor (TLR) ligands during acute
inﬂammation [8,19,20]. In this study sTREM-1 levels were
found to be signiﬁcantly elevated in patients with RA as com-
pared to healthy controls. The data presented here demon-
strate that sTREM-1 has an important role in RA, a disease
in which persistent inﬂammation with subsequent progressive
destruction of the bone and joint appears to play an indispens-
able role in the disease pathogenesis. The role of TREM-1 in
mediating inﬂammatory response has been conﬁrmed in acute
and chronic inﬂammatory conditions [10,21–23]. TREM-1 is
expressed in high levels in acute infectious lesions caused by
bacteria and fungi [10]. Furthermore, it has been found ele-
vated in murine models of septic shock, experimental acute
pancreatitis and experimental inﬂammatory bowel diseases
[21–23]. As well, the role of TREM-1 has been studied in hu-
man autoimmune diseases [24–27]. Plasma TREM-1 was ele-
vated in patients with Behcet’s and Crohn’s disease [13,24].
Furthermore, genetic polymorphism in TREM-1 has been
found to be associated with inﬂammatory bowel diseases in
the Korean population [25]. Tomita et al. [26] studied the clin-
ical signiﬁcance of TREM-1 in patients with systemic sclerosis
(SSc) and found that serum sTREM-1 levels were elevated in
patients with diffuse cutaneous systemic sclerosis than those
with the limited sub type. They were able to correlate these
data with the severity of pulmonary ﬁbrosis, suggesting that
serum sTREM-1 is a novel serological marker for the disease
severity of SSc. The possible role of sTREM-1 in ankylosing
spondylitis (AS) had been studied and sTREM-1 seems to be
a new mediator involved in patients with AS, particularly in
the early stages of disease [27].
Here we found that sTREM-1 correlated signiﬁcantly with
disease activity, both clinically and the laboratory. Serum lev-
els of sTREM-1 were higher in patients with elevated ESR. As
well, sTREM-1 levels were elevated in patients with severe dis-
ease activity (DAS > 5.1) than those with mild disease activity
(DAS < 3.2), a ﬁnding which suggests that sTREM-1 may re-
ﬂect a degree of systemic inﬂammation. TREM-1 expression is
Figure 1 Serum levels of sTREM-1 (ng/ml) in RA patients and healthy controls.
Figure 2 Serum sTREM-1 levels (ng/ml) in RA patients with different grades of disease activity.
98 S.A. El Bakry et al.increased by various TLR ligands during acute inﬂammation
with subsequent increase in the production of pro-inﬂamma-
tory cytokines [8,19,20]. This was conﬁrmed by in vitro studies
which have revealed that stimulation of synovial cells, isolated
from synovial tissue specimens of RA patients, by TREM-1
showed increased cytokine production such as; TNFa, IL-8,
IL-1b, GM-CSF as compared to controls. This suggests that
TREM-1 contributes in amplifying inﬂammation in arthritis
[14]. Similarly, Collins and coworkers have assessed the
TREM-1 synovial expression in patients with distinct types
of inﬂammatory and non-inﬂammatory arthritis [11]. They
have reported comparable increase of sTREM-1 levels in septic
arthritis and RA which were greater than those in gouty arthri-
tis and non-inﬂammatory arthritis [11].Two recent studies have found elevated sTREM-1 levels in
RA patients than controls with signiﬁcant association to clin-
ical and laboratory parameters of disease activity, although
sTREM-1 relation with the radiological damage or the func-
tional capacity have not been discussed [14,28]. In the present
study, elevated serum sTREM-1 was signiﬁcantly higher in RA
patients with deteriorated functional capacity. On the other
hand, sTREM-1 was not correlated with radiological damage,
neither narrowing score nor erosion score.
Biologic agents blocking the action of inﬂammatory cyto-
kines have been able to suppress progression inﬂammation
and joint destruction in RA patients [3]. However, some RA
patients, about one third, fail to achieve complete remission.
As well, serious bacterial infection and reactivation of
Table 2 Correlation between sTREM-1 levels (ng/ml) and
some RA disease parameters.
Variable r P
Age (years) 0.019 0.860
Disease duration (years) 0.118 0.366
Morning stiﬀness (minutes) 0.209 0.107
DAS-28 0.405 0.001**
mHAQ 0.372 0.003*
ESR (mm/hr) 0.297 0.020*
Hemoglobin (g/dl) 0.078 0.551
Leucocytes (·1000/ll) 0.182 0.161
Platelets (·1000/ll) 0.093 0.478
DAS: disease activity score, mHAQ: modiﬁed health assessment
questionnaire, ESR: erythrocyte sedimentation rate.
* High signiﬁcant difference.
** Very high signiﬁcant difference.
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Figure 3 Scatter plot demonstrating correlation of serum
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observed [4]. Targeting TREM-1 signaling may be used as a
therapeutic strategy in RA. The administration of TREM-1 fu-
sion protein in experimental collagen type II induced arthritis
in mice has been associated with a signiﬁcant reduction of clin-
ical signs in a dose-dependent manner [29]. Further, it was
hypothesized that modulating the actions of TREM-1 may
be a safe therapeutic strategy for RA, as blocking TREM-1
signaling was found to suppress inﬂammatory responses with-
out affecting the ability of the immune system to ﬁght bacterial
infection [30,31].
In conclusion, we have demonstrated high levels of
sTREM-1 in the sera of RA patients compared to healthy con-
trols. In addition, we have reported that serum levels of
sTREM-1 are related to symptoms and signs of disease activ-
ity, as well as functional scores of RA patients. To conﬁrm our
results we propose that larger scale, multicenter studies with
longer evaluation periods are needed.mHAQ
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